We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pyoderma Gangrenosum: Treatment Options.
- Authors
Dissemond, Joachim; Marzano, Angelo V.; Hampton, Philip J.; Ortega-Loayza, Alex G.
- Abstract
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
- Subjects
TREATMENT of rare diseases; INTERLEUKINS; BIOLOGICAL products; TUMOR necrosis factors; PYODERMA gangrenosum; PHARMACEUTICAL chemistry; EARLY medical intervention; CHEMICAL inhibitors
- Publication
Drugs, 2023, Vol 83, Issue 14, p1255
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-023-01931-3